CVAC Systems and TempusClinic Partner to Study the Potential Value of the CVAC Process in Managing and Treating Diabetes, Insulin Resistance, and Metabolic Syndrome

“TempusClinic’s current patient base includes over 70 Silicon Valley CEOs and VCs as well as over a dozen international elite-level athletes. We are extremely pleased with this partnership.” -Allen J. Ruszkowski, President/CEO, CVAC Systems

Temecula, CA; Los Gatos, CA (PRWEB) September 27, 2006 -- CVAC Systems, Inc. (www.cvacsystems.com) announced today an agreement with Los Gatos, Calif.-based TempusClinic to study the potential value of the CVAC process in managing and treating diabetes, insulin resistance, and metabolic syndrome. The study is expected to commence next month.

CVAC Systems has developed a new, noninvasive modality for the treatment of metabolic derangement, which includes diabetes, insulin resistance, and metabolic syndrome. Data published in respected peer-reviewed journals have shown significant improvement in metabolic insulin efficiency and glycemic control (in animals and man) with the use of intermittent hypoxic (high altitude) training (IHT). Cyclic Variations in Altitude Conditioning (CVAC) is a scientifically validated IHT process which triggers the human body’s natural high-altitude adaptation response. CVAC, however, produces the beneficial effects of high-altitude adaptation via IHT while significantly reducing the required exposure time for IHT. Other techniques providing IHT require exposure ranging from 21 to 84 hours per week; CVAC exposures require less than 4.5 hours per week.

“There are more than 90 million individuals in the U.S. and some 200 million worldwide who suffer from metabolic derangement,” said Allen J. Ruszkowski, President and CEO of CVAC Systems. “The cost of treating diabetes alone, which is just one of the forms of metabolic derangement, is over $125 billion annually in the U.S. In addition, there are an estimated 50 million Americans with metabolic syndrome, another form of metabolic derangement, who have a fivefold increased probability of developing diabetes and a twofold increased risk in developing cardiovascular disease. Currently, physicians lack a successful treatment regimen to help their patients other than browbeating the patient to change diet, lose weight and exercise, which has very poor compliance.”

“TempusClinic uses a four-part integrated program to help our clients achieve metabolic turnaround. We combine the best of today’s science, the most advanced technologies, and the most natural means by which our clients may achieve their health and fitness goals,” added Mike Nichols, M.D., CEO and Founder of TempusClinic. “We are, therefore, very interested in studying the CVAC process, which we believe will go hand-in-hand with our programs. We are always looking for scientifically validated non-invasive, non-toxic approaches to health advancement,” said Dr. Nichols.

About TempusClinic
Founded in 2001, TempusClinic is the leader in personalized preventative health care. Located in Los Gatos, Calif., TempusClinic is comprised of a team of renowned physicians, fitness trainers, and medical professionals who are committed to health excellence in a caring, supportive and educational environment. Dr. Mike Nichols' background in scientific theory construction at the University of Chicago, where he obtained his first graduate degree in the Philosophy of Science, led him to question current medical approaches to complex medical problems and led him eventually to found the TempusClinic. His medical degree is from Loyola University of Chicago and residency from Stanford University. He practiced medicine for 20 years prior to developing TempusClinic

About CVAC Systems
CVAC Systems, Inc., headquartered in Temecula, Calif., is privately funded and is seeking to place CVAC instruments (pressure vessels) at key luminary research sites for the development of several patent-pending applications such as performance enhancement, disease prevention, therapy and advanced health. For these plans, the Company is seeking a first-round venture/institutional financing.

Please note: The information contained within this document is intended for prospective investors only, and is not intended for patients or health care providers. Any references to therapeutic applications are for discussion and research purposes only.

###